Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 33% Improvement Relative Risk ARDS 68% HCQ for COVID-19  Ouedraogo et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 456 patients in Burkina Faso Lower severe cases with HCQ (p=0.001) c19hcq.org Ouedraogo et al., Revue des Maladies R.., Feb 2021 Favors HCQ Favors control

Factors associated with the occurrence of acute respiratory distress and death in patients with COVID-19 in Burkina Faso

Ouedraogo et al., Revue des Maladies Respiratoires, doi:10.1016/j.rmr.2021.02.001
Feb 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19hcq.org
Retrospective 456 patients in Burkina Faso showing lower risk of ARDS (p=0.001) and mortality (p=0.38) with HCQ.
risk of death, 33.0% lower, HR 0.67, p = 0.38, treatment 397, control 59, multivariate.
risk of ARDS, 68.0% lower, OR 0.32, p = 0.001, treatment 397, control 59, multivariate, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ouedraogo et al., 5 Feb 2021, retrospective, Burkina Faso, peer-reviewed, 14 authors.
This PaperHCQAll
Facteurs associés à la survenue de la détresse respiratoire aiguë et au décès chez des patients atteints de COVID-19 au Burkina Faso
A R Ouédraogo, G Bougma, A Baguiya, A Sawadogo, P R Kaboré, C J Minougou, A Diendéré, S Maiga, C R Agbaholou, A Hema, A Sondo, G Ouédraogo, A Sanou, M Ouedraogo
Revue des Maladies Respiratoires, doi:10.1016/j.rmr.2021.02.001
MOTS CLÉS COVID 19 ; Détresse respiratoire aiguë ; Décès ; Burkina Faso Résumé Introduction. -L'apparition d'un syndrome de détresse respiratoire aiguë constitue une des formes graves de la COVID-19. Bien qu'il y ait eu plusieurs études sur les facteurs pronostiques de sa forme sévère, aucune étude de ce type n'a été menée au Burkina Faso. Méthodes. -Il s'agit d'une étude de cohorte rétrospective conduite du 09 mars au 09 juin 2020 à Ouagadougou, Burkina Faso et qui a concerné 456 patients atteints de COVID-19. Résultats. -Près d'un quart des patients (23,2 %) avaient présenté une détresse respiratoire aiguë et 44,3 % d'entre eux en sont décédés. Un âge supérieur à 65 ans (HR :2,7 ; IC95 % : 1,5-5,1) et avoir une HTA (HR :1,9 ; IC95 % : 1-3,5) étaient indépendamment associés au risque de mortalité. Cependant, après ajustement, seul l'âge supérieur à 65 ans (HR :2,3 ; IC95 % : 1,2-4,3) était un facteur de risque de décès. Le taux de survie des patients de plus de 65 ans était à 7 jours de 38,5 % et 30,3 % à 15 jours. Conclusion. -La détresse respiratoire aiguë conduisant au décès est essentiellement retrouvée chez des sujets d'âge avancé atteints de la COVID-19. Une surveillance étroite de ces patients à haut risque peut permettre de réduire la létalité.
References
Chen, Dai, Mo, Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study, J Gerontol A Biol Sci Med Sci
Horby, Lim, Emberson, Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report, N Engl J Med
Jang, Hur, Choi, Prognostic Factors for Severe Coronavirus Disease 2019 in Daegu, Korea, J Korean Med Sci
Li, Xu, Yu, Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan, J Allergy Clin Immunol
Livingston, Bucher, Coronavirus Disease 2019 (COVID-19) in Italy, JAMA
Magagnoli, Narendran, Pereira, Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19, Med (N Y)
Mahévas, Tran, Roumier, Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data, BMJ
Placais, Richier, COVID-19: caractéristiques cliniques, biologiques et radiologiques chez l'adulte, la femme enceinte et l'enfant. Une mise au point au coeur de la pandémie, Rev Med Intern
Rosenberg, Dufort, Udo, Association of Treatment with Hydroxychloroquine or Azithromycin with in-Hospital Mortality in Patients with COVID-19 in New York State, JAMA
Shang, Zhao, Hu, On the use of corticosteroids for 2019-nCoV pneumonia, Lancet
Shi, Yu, Zhao, Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan, Crit Care
Stawicki, Jeanmonod, Miller, The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper, J Glob Infect Dis
Tang, Cao, Han, Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease2019: open label, randomized controlled trial, BMJ
Wei, Wang, Zhang, Risk factors for severe COVID-19: Evidence from 167 hospitalized patients in Anhui, China, J Infect
Wu, Chen, Cai, Risk Factors Associated With Acute RespiratoryDistress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China, JAMA Intern Med
Wu, Chen, Cai, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med
Wu, Ho, Huang, SARS-CoV-2 is an appropriate name for the new coronavirus, Lancet
Wu, Li, Shi, Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19), J Intern Med
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention, JAMA
Zhang, Wang, Jia, Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China, Clin Microbiol Infect
Zhao, Hu, Du, Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Chinese journal of tuberculosis and respiratory diseases
Zhou, Liu, Tian, Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia, Signal Transduct Target Ther
Zhou, Yu, Du, Clinical course and risk factors formortality of adult in patients with COVID-19 in Wuhan, China: a retrospectivecohort study, Lancet
Zhu, Zhang, Wang, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med
Zucker, Baldwin, Hripcsak, Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl J Med
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit